Last reviewed · How we verify
tislelizumab, and platinum-based chemotherapy
tislelizumab, and platinum-based chemotherapy is a Small molecule drug developed by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. It is currently in Phase 3 development.
Tislelizumab is a monoclonal antibody that targets and binds to PD-1, blocking its interaction with PD-L1 and PD-L2, thereby enhancing T-cell mediated immune response against cancer cells.
At a glance
| Generic name | tislelizumab, and platinum-based chemotherapy |
|---|---|
| Sponsor | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
By binding to PD-1, tislelizumab prevents the PD-1/PD-L1/PD-L2 pathway from inhibiting T-cell activation and proliferation, leading to increased anti-tumor immune response. This mechanism is thought to be responsible for its anti-tumor effects when used in combination with platinum-based chemotherapy.
Approved indications
Common side effects
Key clinical trials
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (PHASE3)
- Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer (PHASE2)
- A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (PHASE3)
- Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC) (PHASE3)
- A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer (PHASE2)
- Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC (PHASE2)
- A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)] (PHASE2)
- Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- tislelizumab, and platinum-based chemotherapy CI brief — competitive landscape report
- tislelizumab, and platinum-based chemotherapy updates RSS · CI watch RSS
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. portfolio CI